文献速递肿瘤 PET/CT放射性药物与辐射防护

高活性ATM抑制剂的放射性氟化作为潜在PET显像剂

Radiofluorination of a highly potent ATM inhibitor as a potential PET imaging agent.
PubMed 文献 · EJNMMI Res · 2022-08-13

本研究合成并评估了首个18F标记的ATM抑制剂[18F]1。放射化学产率为20±13%(衰减校正),摩尔活度最高达79.5 GBq/μmol(n=11)。体外[18F]1与ATM表达不相关,但可被已知ATM抑制剂显著阻断,显示特异性结合;体内可见快速肝胆清除。

要点

  • 首个18F标记ATM抑制剂[18F]1的放射化学产率为20±13%(衰减校正),摩尔活度最高79.5 GBq/μmol(n=11)。
  • 体外[18F]1摄取与ATM表达不相关,但可被过量已知ATM抑制剂显著降低,显示特异性结合ATM。
  • 体内见快速肝胆清除,肿瘤摄取在1小时后为0.13-0.90%ID/g。

核心结论

  • 本研究首次报道了ATM抑制剂的放射性氟化及其体外和体内生物学评价,揭示了18F标记ATM抑制剂的优势但也存在一些局限性。

研究设计与样本

  • 通过用[18F]氟化物取代硝基前体实现选择性ATM抑制剂1的放射性氟化。
  • 体外用稳定转染shRNA以降低ATM表达的H1299肺癌细胞评估[18F]1摄取,并用多种非放射性ATM抑制剂进行阻断实验评估结合特异性。
  • 在野生型和ATM敲除C57BL/6小鼠中用PET/CT及离体分析进行体内生物分布研究。
  • 在BALB/c nu/nu小鼠中评估H1299肿瘤异种移植物的[18F]1摄取。

主要发现

  • 硝基前体2的总产率为12%。
  • 2的放射性氟化在80±13分钟内获得放射化学纯的[18F]1,放射化学产率为20±13%(衰减校正),摩尔活度最高达79.5 GBq/μmol(n=11)。
  • 体外[18F]1的细胞相关放射性在1小时内增加,[18F]1的滞留率在2小时内降至50%。
  • [18F]1摄取与ATM表达不相关,但可被过量已知ATM抑制剂显著降低。
  • 体内观察到快速肝胆清除,1小时后肿瘤摄取范围为0.13-0.90%ID/g。

局限性

  • 本研究揭示了18F标记ATM抑制剂的一些局限性,但原文未具体列出局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ataxia telangiectasia mutated (ATM) is a key mediator of the DNA damage response, and several ATM inhibitors (ATMi) are currently undergoing early phase clinical trials for the treatment of cancer. A radiolabelled ATMi to determine drug pharmacokinetics could assist patient selection in a move towards more personalised medicine. The aim of this study was to synthesise and investigate the first 18F-labelled ATM inhibitor [18F]1 for non-invasive imaging of ATM protein and ATMi pharmacokinetics. METHODS: Radiofluorination of a confirmed selective ATM inhibitor (1) was achieved through substitution of a nitro-precursor with [18F]fluoride. Uptake of [18F]1 was assessed in vitro in H1299 lung cancer cells stably transfected with shRNA to reduce expression of ATM. Blocking studies using several non-radioactive ATM inhibitors assessed binding specificity to ATM. In vivo biodistribution studies were performed in wild-type and ATM-knockout C57BL/6 mice using PET/CT and ex vivo analysis. Uptake of [18F]1 in H1299 tumour xenografts was assessed in BALB/c nu/nu mice. RESULTS: Nitro-precursor 2 was synthesised with an overall yield of 12%. Radiofluorination of 2 achieved radiochemically pure [18F]1 in 80 ± 13 min with a radiochemical yield of 20 ± 13% (decay-corrected) and molar activities up to 79.5 GBq/μmol (n = 11). In vitro, cell-associated activity of [18F]1 increased over 1 h, and retention of [18F]1 dropped to 50% over 2 h. [18F]1 uptake did not correlate with ATM expression, but could be reduced significantly with an excess of known ATM inhibitors, demonstrating specific binding of [18F]1 to ATM. In vivo, fast hepatobiliary clearance was observed with tumour uptake ranging 0.13-0.90%ID/g after 1 h. CONCLUSION: Here, we report the first radiofluorination of an ATM inhibitor and its in vitro and in vivo biological evaluations, revealing the benefits but also some limitations of 18F-labelled ATM inhibitors.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Fraser CR, Ajenjo J, Veal M, et al. Radiofluorination of a highly potent ATM inhibitor as a potential PET imaging agent. EJNMMI Res. 2022. PMID: 35962885. doi:10.1186/s13550-022-00920-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。